Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2019 11:30 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 15, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial...
May 08, 2019 16:05 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights

Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis...
May 01, 2019 07:00 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8th, 2019 at 4:30...
April 29, 2019 16:05 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank

SOUTH SAN FRANCISCO, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon...
April 03, 2019 07:00 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President,...
March 07, 2019 16:01 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2018....
March 04, 2019 07:00 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor conferences...
February 28, 2019 07:00 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, March 7th, 2019 at 4:30...
January 17, 2019 21:58 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Pricing of $20 Million Offering of Securities

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of...
January 17, 2019 16:05 ET | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions,...